NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 231 filers reported holding NEVRO CORP in Q4 2020. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $394,000 | -15.5% | 8,456 | +31.3% | 0.02% | -7.7% |
| Q1 2022 | $466,000 | -37.3% | 6,438 | -29.7% | 0.03% | -7.1% |
| Q4 2021 | $743,000 | +57.1% | 9,159 | +125.2% | 0.03% | +16.7% |
| Q3 2021 | $473,000 | -42.4% | 4,067 | -30.9% | 0.02% | -47.8% |
| Q1 2021 | $821,000 | +42.8% | 5,886 | +42.6% | 0.05% | -25.8% |
| Q3 2020 | $575,000 | +38.2% | 4,128 | +18.5% | 0.06% | -10.1% |
| Q2 2020 | $416,000 | +107.0% | 3,483 | +73.5% | 0.07% | +187.5% |
| Q1 2020 | $201,000 | – | 2,008 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tiger Eye Capital LLC | 239,122 | $41,392,000 | 8.25% |
| Integral Health Asset Management, LLC | 88,000 | $15,233,000 | 4.53% |
| Iron Triangle Partners LP | 168,761 | $29,213,000 | 3.79% |
| Eos Focused Equity Management, L.P. | 14,002 | $2,424,000 | 2.37% |
| PFM Health Sciences, LP | 311,940 | $53,997,000 | 1.90% |
| Perceptive Advisors | 977,565 | $169,217,000 | 1.82% |
| Rock Springs Capital Management LP | 395,000 | $68,375,000 | 1.45% |
| Lisanti Capital Growth, LLC | 54,302 | $9,400,000 | 1.30% |
| HealthCor Management, L.P. | 156,046 | $27,012,000 | 1.04% |
| FRED ALGER MANAGEMENT, LLC | 2,136,612 | $369,848,000 | 0.96% |